Park Avenue Compounding Recalls Fentanyl Citrate/Ropivacaine Due to CGMP Deviations
Park Avenue Compounding has initiated a Class II recall (D-0178-2026) for 189 bags of Fentanyl citrate / Ropivacaine combination, a Schedule II controlled substance, distributed in Missouri. The recall stems from Current Good Manufacturing Practice (CGMP) deviations, specifically a revised interpretation of Acceptable Quality Level (AQL) results. This event highlights critical compliance risks in sterile compounding, necessitating immediate review of quality control protocols for pharmaceutical procurement and regulatory compliance teams.
FDA-Mandated Recall for CGMP Deviations in Sterile Compounding
Park Avenue Compounding, located at 3662 Park Ave Ste 140, Saint Louis, MO 63110-2512, initiated a Class II recall (D-0178-2026) on September 23, 2025, for 189 bags of Fentanyl citrate, 2 mcg/ml / Ropivacaine, 0.2% in NS 150 mL. This product, identified by NDC 83863-4272-1 and Lot # 20250507-01D93C with an expiration date of November 4, 2025, is a Schedule II controlled substance, underscoring the criticality of its quality assurance. The primary reason cited for this voluntary, firm-initiated recall is "CGMP Deviations: Revised interpretation of Acceptable Quality Level (AQL) results." For procurement and regulatory affairs teams, this signifies a fundamental breakdown in quality control processes. A misinterpretation of AQL results suggests that batches previously deemed acceptable may not have met the required quality standards, potentially exposing patients to substandard or contaminated products. This event necessitates an immediate audit of internal and supplier quality systems to ensure AQL methodologies align with FDA expectations, particularly for high-risk sterile compounded drugs.
Product and Facility Profile: Localized Impact for a Critical Opioid Combination
The recalled product, Fentanyl citrate / Ropivacaine in normal saline, is a combination anesthetic and analgesic, classified as a Schedule II controlled substance. Its use in patient care, particularly for pain management, demands stringent quality and sterility. The recall's distribution pattern is explicitly stated as "Distributed in Missouri," indicating a localized supply chain impact. While the facility in Saint Louis, MO, serves a regional market, the implications of CGMP deviations for such a critical drug extend beyond geographical boundaries. For business development executives and supply chain VPs, this highlights the inherent risks associated with sourcing from compounding pharmacies, even for regional distribution. The absence of detailed facility capacity or broader market reach information in the available data means that direct global supply chain exposure from this specific facility is limited. However, the incident serves as a critical reminder for all stakeholders to rigorously vet regional compounding partners, ensuring their quality systems for controlled substances meet federal standards, regardless of their operational scale or distribution footprint.
Supply Chain Risk and Remediation for Compounded Sterile Preparations
The CGMP deviations related to AQL interpretation at Park Avenue Compounding present a direct supply chain risk for healthcare providers and procurement directors relying on compounded sterile preparations. The Class II classification of this recall indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, for a Schedule II opioid like Fentanyl, any deviation from quality standards is highly concerning. Supply chain VPs must assess their reliance on single-source compounding facilities, especially for critical care medications. While the knowledge graph does not identify alternative suppliers for this specific Fentanyl citrate / Ropivacaine combination, the broader market for compounded sterile products includes numerous pharmacies. Procurement teams should proactively identify and qualify multiple alternative compounding pharmacies with robust quality management systems to prevent supply disruptions and ensure patient safety. This incident underscores the need for continuous monitoring of regulatory intelligence, even for localized recalls, to inform strategic sourcing decisions and mitigate potential compliance liabilities across the pharmaceutical supply chain.